| Year |
Citation |
Score |
| 2024 |
Landberg N, Köhnke T, Feng Y, Nakauchi Y, Fan AC, Linde MH, Karigane D, Lim K, Sinha R, Malcovati L, Thomas D, Majeti R. IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation. Blood Cancer Discovery. OF1-OF18. PMID 38261864 DOI: 10.1158/2643-3230.BCD-23-0195 |
0.617 |
|
| 2023 |
Landberg N, Köhnke T, Feng Y, Nakauchi Y, Fan AC, Linde MH, Karigane D, Lim K, Sinha R, Malcovati L, Thomas D, Majeti R. IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation. Blood Cancer Discovery. PMID 38091010 DOI: 10.1158/2643-3230.BCD-23-0195 |
0.615 |
|
| 2023 |
Foßelteder J, Pabst G, Sconocchia T, Schlacher A, Auinger L, Kashofer K, Beham-Schmid C, Trajanoski S, Waskow C, Schöll W, Sill H, Zebisch A, Wölfler A, Thomas D, Reinisch A. Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. Leukemia. PMID 36813992 DOI: 10.1038/s41375-023-01848-6 |
0.679 |
|
| 2023 |
Thompson-Peach CAL, Foßelteder J, Reinisch A, Thomas D. Thrombopoietin-independent Megakaryocyte Differentiation of Hematopoietic Progenitor Cells from Patients with Myeloproliferative Neoplasms. Bio-Protocol. 13: e4592. PMID 36789162 DOI: 10.21769/BioProtoc.4592 |
0.622 |
|
| 2022 |
Thomas D, Wu M, Nakauchi Y, Zheng M, Thompson-Peach CA, Lim K, Landberg N, Köhnke T, Robinson N, Kaur S, Kutyna M, Stafford M, Hiwase D, Reinisch A, Peltz G, et al. Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery. PMID 36355448 DOI: 10.1158/2159-8290.CD-21-0218 |
0.72 |
|
| 2022 |
Bassal MA, Samaraweera SE, Lim K, Benard BA, Bailey S, Kaur S, Leo P, Toubia J, Thompson-Peach C, Nguyen T, Maung KZY, Casolari DA, Iarossi DG, Pagani IS, Powell J, ... ... Thomas D, et al. Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications. 13: 4131. PMID 35840577 DOI: 10.1038/s41467-022-31952-7 |
0.556 |
|
| 2022 |
Bassal MA, Samaraweera SE, Lim K, Bernard BA, Bailey S, Kaur S, Leo P, Toubia J, Thompson-Peach C, Nguyen T, Maung KZY, Casolari DA, Iarossi DG, Pagani IS, Powell J, ... ... Thomas D, et al. Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications. 13: 2614. PMID 35551192 DOI: 10.1038/s41467-022-30223-9 |
0.592 |
|
| 2022 |
Nakauchi Y, Azizi A, Thomas D, Corces MR, Reinisch A, Sharma R, Cruz Hernandez D, Kohnke T, Karigane D, Fan A, Martinez-Krams D, Stafford M, Kaur S, Dutta R, Phan P, et al. The cell type specific 5hmC landscape and dynamics of healthy human hematopoiesis and TET2-mutant pre-leukemia. Blood Cancer Discovery. PMID 35532363 DOI: 10.1158/2643-3230.BCD-21-0143 |
0.802 |
|
| 2022 |
Lewis AC, Pope VS, Tea MN, Li M, Nwosu GO, Nguyen TM, Wallington-Beddoe CT, Moretti PA, Anderson D, Creek DJ, Costabile M, Ali SR, Thompson-Peach CA, Dredge BK, Bert AG, ... ... Thomas D, et al. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood. PMID 35443029 DOI: 10.1182/blood.2021013277 |
0.303 |
|
| 2022 |
Tvorogov D, Thompson-Peach CAL, Foßelteder J, Dottore M, Stomski F, Onnesha SA, Lim K, Moretti PAB, Pitson SM, Ross DM, Reinisch A, Thomas D, Lopez AF. Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody. Embo Reports. e52904. PMID 35156745 DOI: 10.15252/embr.202152904 |
0.656 |
|
| 2021 |
Benard BA, Leak LB, Azizi A, Thomas D, Gentles AJ, Majeti R. Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia. Nature Communications. 12: 7244. PMID 34903734 DOI: 10.1038/s41467-021-27472-5 |
0.571 |
|
| 2020 |
Dutta R, Zhang TY, Köhnke T, Thomas D, Linde M, Gars E, Stafford M, Kaur S, Nakauchi Y, Yin R, Azizi A, Narla A, Majeti R. Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2. The Journal of Clinical Investigation. PMID 31895700 DOI: 10.1172/Jci133344 |
0.612 |
|
| 2019 |
Guan Y, Chen X, Wu M, Zhu W, Arslan A, Takeda S, Nguyen MH, Majeti R, Thomas D, Zheng M, Peltz G. The Phosphatidylethanolamine Biosynthesis Pathway Provides a New Target for Cancer Chemotherapy. Journal of Hepatology. PMID 31760071 DOI: 10.1016/J.Jhep.2019.11.007 |
0.536 |
|
| 2019 |
Li Y, Thomas D, Deutzmann A, Majeti R, Felsher DW, Dill DL. Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Scientific Reports. 9: 16775. PMID 31727951 DOI: 10.1038/S41598-019-53290-3 |
0.627 |
|
| 2019 |
Benard B, Gentles AJ, Köhnke T, Majeti R, Thomas D. Data mining for mutation-specific targets in acute myeloid leukemia. Leukemia. PMID 30728456 DOI: 10.1038/S41375-019-0387-Y |
0.629 |
|
| 2019 |
Wang W, Awani A, Devilbiss A, Mathews T, Thomas D, Dever DP, Porteus M, Morrison S, Weinacht KG. Adenylate Kinase 2 Links Energy Metabolism and Cell Fate in Hematopoietic Stem and Progenitor Cells Blood. 134: 3705-3705. DOI: 10.1182/Blood-2019-129424 |
0.413 |
|
| 2019 |
Dutta R, Zhang TY, Koehnke T, Thomas D, Gars E, Stafford M, Nakauchi Y, Kaur S, Yin R, Narla A, Majeti R. Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2 Blood. 134: 540-540. DOI: 10.1182/Blood-2019-124551 |
0.554 |
|
| 2019 |
Powell J, Lewis A, Tea M, Nguyen T, Wallington-Beddoe C, Anderson D, Creek D, D'Andrea R, Ross D, Thomas D, Pitson S. Ceramide Evokes An Apoptotic Integrated Stress Response In Acute Myeloid Leukemia Experimental Hematology. 76. DOI: 10.1016/J.Exphem.2019.06.424 |
0.406 |
|
| 2018 |
Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Majeti R, Babon JJ, et al. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances. 4: eaat3834. PMID 30498775 DOI: 10.1126/Sciadv.Aat3834 |
0.575 |
|
| 2018 |
Wang W, Awani A, Reich L, Nakauchi Y, Thomas D, Dever DP, Porteus M, Weinacht KG. An Engineered Cell-Traceable Model of Reticular Dysgenesis in Human Hematopoietic Stem Cells Linking Metabolism and Differentiation Blood. 132: 2558-2558. DOI: 10.1182/Blood-2018-99-117926 |
0.344 |
|
| 2018 |
Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Babon JJ, Majeti R, et al. Accumulation of JAK Activation-Loop Phosphorylation Promotes Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis Blood. 132: 1787-1787. DOI: 10.1182/Blood-2018-99-115760 |
0.544 |
|
| 2018 |
Thomas D, Nakauchi Y, Wu M, Zheng M, Sinha S, Dill D, Peltz G, Majeti R. IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML Blood. 132: 440-440. DOI: 10.1182/Blood-2018-99-115040 |
0.646 |
|
| 2018 |
Nakauchi Y, Thomas D, Sharma R, Corces MR, Reinisch A, Cruz D, Koehnke T, Karigane D, Fan A, Majeti R. Azacitidine and Ascorbate Inhibit the Competitive Outgrowth of Human TET2 Mutant HSPCs in a Xenograft Model of Pre-Leukemia Blood. 132: 887-887. DOI: 10.1182/Blood-2018-99-113907 |
0.751 |
|
| 2017 |
Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernards R, Majeti R, Dill DL. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications. 8: 15580. PMID 28561042 DOI: 10.1038/Ncomms15580 |
0.781 |
|
| 2017 |
Thomas D, Majeti R. Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models. Cancer Discovery. 7: 459-461. PMID 28461409 DOI: 10.1158/2159-8290.Cd-17-0270 |
0.613 |
|
| 2017 |
Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. PMID 28159741 DOI: 10.1182/Blood-2016-10-696054 |
0.622 |
|
| 2017 |
Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Bernards R, Majeti R, Dill DL. Abstract A27: Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer primary tumor data Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A27 |
0.789 |
|
| 2016 |
Powell JA, Lewis AC, Zhu W, Toubia J, Pitman MR, Wallington-Beddoe CT, Moretti PA, Iarossi D, Samaraweera SE, Cummings N, Ramshaw HS, Thomas D, Wei AH, Lopez AF, D'Andrea RJ, et al. Targeting sphingosine kinase 1 induces MCL1 dependent cell death in acute myeloid leukemia. Blood. PMID 27956387 DOI: 10.1182/Blood-2016-06-720433 |
0.405 |
|
| 2016 |
Huang M, Garcia JS, Thomas D, Zhu L, Nguyen LX, Chan SM, Majeti R, Medeiros BC, Mitchell BS. Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget. PMID 27732946 DOI: 10.18632/Oncotarget.12493 |
0.688 |
|
| 2016 |
Thomas D, Majeti R. Burning Fat Fuels Leukemic Stem Cell Heterogeneity. Cell Stem Cell. 19: 1-2. PMID 27392217 DOI: 10.1016/J.Stem.2016.06.014 |
0.576 |
|
| 2016 |
Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, et al. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget. PMID 27329844 DOI: 10.18632/Oncotarget.10167 |
0.392 |
|
| 2016 |
Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, Schallmoser K, Strunk D, Majeti R. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nature Medicine. PMID 27213817 DOI: 10.1038/Nm.4103 |
0.719 |
|
| 2016 |
Thomas D, Sinha S, Chan SM, Wu M, Torabi D, Peltz G, Gao Y, Dill DL, Majeti R. Isocitrate Dehydrogenase 1 Mutant Cancers Are Metabolically Vulnerable to Inhibition of Acetyl CoA Carboxylase Via a 2-Hydroxyglutarate Independent Mechanism Blood. 128: 1054-1054. DOI: 10.1182/Blood.V128.22.1054.1054 |
0.664 |
|
| 2015 |
Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces MR, Flynn RA, Buenrostro JD, Chan SM, Thomas D, Koenig JL, Hong WJ, Chang HY, Majeti R. Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell. PMID 26607380 DOI: 10.1182/Blood.V126.23.841.841 |
0.775 |
|
| 2015 |
Raval A, Behbehani GK, Nguyen le XT, Thomas D, Kusler B, Garbuzov A, Ramunas J, Holbrook C, Park CY, Blau H, Nolan GP, Artandi SE, Mitchell BS. Reversibility of Defective Hematopoiesis Caused by Telomere Shortening in Telomerase Knockout Mice. Plos One. 10: e0131722. PMID 26133370 DOI: 10.1371/Journal.Pone.0131722 |
0.386 |
|
| 2015 |
Reinisch A, Chan SM, Thomas D, Majeti R. Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Seminars in Hematology. 52: 150-64. PMID 26111462 DOI: 10.1053/J.Seminhematol.2015.03.008 |
0.775 |
|
| 2015 |
Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, Majeti R. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine. 21: 178-84. PMID 25599133 DOI: 10.1038/Nm.3788 |
0.723 |
|
| 2015 |
Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood. 125: 249-60. PMID 25406351 DOI: 10.1182/Blood-2014-04-572255 |
0.735 |
|
| 2015 |
Sinha S, Thomas D, Yu L, Gentles AJ, Jung N, Corces-Zimmerman MR, Chan SM, Reinisch A, Feinberg AP, Dill DL, Majeti R. Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood. 125: 316-26. PMID 25398938 DOI: 10.1182/Blood-2014-03-566018 |
0.785 |
|
| 2015 |
Sinha S, Thomas D, Chan SM, Gao Y, Jansen R, Majeti R, Dill DL. Boolean Implication Mining for Synthetic Lethal Interactions in AML Identifies Acetyl-CoA Carboxylase As a Synthetic Lethal Partner of the IDH1 mutation Blood. 126: 1404-1404. DOI: 10.1182/Blood.V126.23.1404.1404 |
0.642 |
|
| 2015 |
Sinha S, Thomas D, Majeti R, Dill DL. Abstract A1-23: Deciphering the cancer methylome with Boolean implications to find novel drivers of aberrant DNA methylation and actionable drug targets Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-B2-20 |
0.625 |
|
| 2015 |
Sinha S, Thomas D, Gao Y, Chan SM, Brunen D, Bernards R, Majeti R, Dill DL. Abstract LB-B07: MiSL: a method for mining synthetic lethal partners of somatic mutations identifies acetyl-CoA carboxylase as a synthetic lethal interactor of the IDH1 mutation in Leukemia Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-B07 |
0.729 |
|
| 2014 |
Thomas D, Sinha S, Yu L, Jung N, Dai B, Gentles AJ, Feinberg AP, Dill D, Majeti R. Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition Blood. 124: 780-780. DOI: 10.1182/Blood.V124.21.780.780 |
0.666 |
|
| 2014 |
Chan SM, Thomas D, Medeiros BC, Majeti R. Isocitrate Dehydrogenase Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia through Inhibition of Cytochrome C Oxidase Function Blood. 124: 615-615. DOI: 10.1182/Blood.V124.21.615.615 |
0.729 |
|
| 2014 |
Thomas D, Sinha S, Gentles A, Jung N, Feinberg A, Dill D, Majeti R. Wilms' tumor 1 mutation drives DNA hypermethylation in AML and responds to EZH2-inhibitor Experimental Hematology. 42: S62. DOI: 10.1016/J.Exphem.2014.07.237 |
0.583 |
|
| 2013 |
George AJ, Purdue BW, Gould CM, Thomas DW, Handoko Y, Qian H, Quaife-Ryan GA, Morgan KA, Simpson KJ, Thomas WG, Hannan RD. A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation. Journal of Cell Science. 126: 5377-90. PMID 24046455 DOI: 10.1242/Jcs.128280 |
0.316 |
|
| 2013 |
Huang M, Thomas D, Li MX, Feng W, Chan SM, Majeti R, Mitchell BS. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia. 27: 1970-80. PMID 23877794 DOI: 10.1038/Leu.2013.222 |
0.717 |
|
| 2013 |
Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, et al. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood. 122: 738-48. PMID 23775716 DOI: 10.1182/Blood-2012-08-447441 |
0.384 |
|
| 2013 |
Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino AC, Pitson SM, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA. Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. Plos Biology. 11: e1001515. PMID 23526884 DOI: 10.1371/Journal.Pbio.1001515 |
0.327 |
|
| 2013 |
Lim YY, Wright JA, Attema JL, Gregory PA, Bert AG, Smith E, Thomas D, Lopez AF, Drew PA, Khew-Goodall Y, Goodall GJ. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. Journal of Cell Science. 126: 2256-66. PMID 23525011 DOI: 10.1242/Jcs.122275 |
0.302 |
|
| 2013 |
Thomas D, Powell JA, Parker MW, Ekert PG, Lock RB, Huang DC, Nilsson SK, Recher C, Wei AH, Guthridge MA. Abstract A19: The selective targeting of cell survival pathways in leukemia Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-A19 |
0.395 |
|
| 2012 |
Hercus TR, Broughton SE, Ekert PG, Ramshaw HS, Perugini M, Grimbaldeston M, Woodcock JM, Thomas D, Pitson S, Hughes T, D'Andrea RJ, Parker MW, Lopez AF. The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors (Chur, Switzerland). 30: 63-75. PMID 22257375 DOI: 10.3109/08977194.2011.649919 |
0.314 |
|
| 2012 |
Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Martin K, Ghosh S, Braley H, Tomasetig V, Panousis C, Vairo G, Roberts AW, He SZ, Sprigg N, Thomas D, et al. CSL362: A Monoclonal Antibody to Human Interleukin-3 Receptor (CD123), Optimized for NK Cell-Mediated Cytotoxicity of AML Stem Cells Blood. 120: 3598-3598. DOI: 10.1182/Blood.V120.21.3598.3598 |
0.373 |
|
| 2011 |
Truong NT, Thomas D, Lonic AK, Powell JA, Guthridge MA. Abstract B158: Targeting cell survival pathways in glioblastoma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B158 |
0.346 |
|
| 2010 |
Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, Sim AT, Ashman LK, Verrills NM. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Research. 70: 5438-47. PMID 20551067 DOI: 10.1158/0008-5472.Can-09-2544 |
0.385 |
|
| 2009 |
Powell JA, Thomas D, Barry EF, Kok CH, McClure BJ, Tsykin A, To LB, Brown A, Lewis ID, Herbert K, Goodall GJ, Speed TP, Asou N, Jacob B, Osato M, et al. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood. 114: 4859-70. PMID 19805619 DOI: 10.1182/Blood-2009-02-204818 |
0.379 |
|
| 2009 |
Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 5: 31-42. PMID 19570512 DOI: 10.1016/J.Stem.2009.04.018 |
0.365 |
|
| 2009 |
Guthridge M, Thomas D, Barry EF, Chung KH, McClure BJ, To LB, Goodall G, Speed TP, Osato M, Haylock D, Nilsson S, D'Andrea R, Lopez A, Powell JA. Expression Profiling of a Hemopoietic Cell Survival Transcriptome Identifies a Functional Prognostic Gene Signature in Normal Karyotype AML. Blood. 114: 1618-1618. DOI: 10.1182/Blood.V114.22.1618.1618 |
0.392 |
|
| 2008 |
Thomas D, Woodcock J, Powell JA, Barry EF, Lopez AF, Guthridge MA. Lipid and Protein Substrates of PI3K in Cytokine Receptor Survival Signalling: Deregulation in Leukemia Blood. 112: 3864-3864. DOI: 10.1182/Blood.V112.11.3864.3864 |
0.339 |
|
| 2008 |
Thomas D, Powell JA, Barry EF, To LB, Lopez A, Guthridge MA. A Molecular Signature for a Cytokine Receptor Survival Pathway in AML Identifies Unique Prognostic Indicators and Therapeutic Targets Blood. 112: 2893-2893. DOI: 10.1182/Blood.V112.11.2893.2893 |
0.37 |
|
| 2005 |
Thomas D, Powell J, Lee S, Lopez AF, Mark G. Primary Acute Myeloid Leukemic Blasts Display Constitutive Serine 585 Phosphorylation within the 14-3-3 Binding Motif of the GM-CSF/IL-3 Receptor Required for Survival Signalling. Blood. 106: 70-70. DOI: 10.1182/Blood.V106.11.70.70 |
0.32 |
|
| 2004 |
Thomas D, Vadas M, Lopez A. Regulation of haematopoiesis by growth factors - emerging insights and therapies. Expert Opinion On Biological Therapy. 4: 869-79. PMID 15174969 DOI: 10.1517/14712598.4.6.869 |
0.325 |
|
| 1993 |
Ollagnon G, Truffaut N, Thomas D, Barbotin J. Effects of anaerobic conditions on biomass production and plasmid stability in an immobilized recombinant E. Coli Biofouling. 6: 317-331. DOI: 10.1080/08927019309386234 |
0.312 |
|
| 1990 |
Huang J, Dhulster P, Thomas D, Barbotin J. Agitation rate effects on plasmid stability in immobilized and free-cell continuous cultures of recombinant E. coli Enzyme and Microbial Technology. 12: 933-939. PMID 1367160 DOI: 10.1016/0141-0229(90)90112-4 |
0.305 |
|
| 1986 |
Poët PdTd, Dhulster P, Barbotin JN, Thomas D. Plasmid inheritability and biomass production: comparison between free and immobilized cell cultures of Escherichia coli BZ18(pTG201) without selection pressure. Journal of Bacteriology. 165: 871-877. PMID 3512527 DOI: 10.1128/Jb.165.3.871-877.1986 |
0.315 |
|
| Show low-probability matches. |